WilmerHale Represents Fulcrum Therapeutics in $80 Million Series B
Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies to unlock gene control and treat serious genetic diseases, today announced the closing of an $80 million Series B financing. The financing was led by Foresite Capital.
The WilmerHale team representing Fulcrum in this transaction included Lia Der Marderosian, Stephanie Singer and Andrea Sorrentino.
Fulcrum’s press release is available at www.fulcrumtx.com.